[1]. M. Yusuf, U. Chawla, N. Haque Ansari, M. Sharma, M. Asif, Perspective on metal-ligand coordination complexes and improvement of current drugs for neurodegenerative diseases (NDDs),
Advanced Journal of Chemistry, Section A,
2023,
6, 31-49. [
Crossref], [
Google Scholar], [
Publisher]
[2]. F. Hooriabad Saboor, A. Ataei, Decoration of metal nanoparticles and metal oxide nanoparticles on carbon nanotubes,
Advanced Journal of Chemistry, Section A,
2024,
7, 122-145. [
Crossref], [
Publisher]
[3]. H. Pourfaraj, M. Zaefizadeh, A. Vojood, Synthesis and characterization of cisplatin magnetic nanocomposite,
Journal of Medicinal and Nanomaterials Chemistry,
2023,
5, 92-105. [
Crossref], [
Google Scholar], [
Publisher]
[4]. U. Ndagi, N. Mhlongo, M.E. Soliman, Metal complexes in cancer therapy–An update from drug design perspective,
Drug Design, Development and Therapy,
2017, 599-616. [
Google Scholar], [
Publisher]
[5]. C. Zhang, C. Xu, X. Gao, Q. Yao, Platinum-based drugs for cancer therapy and anti-tumor strategies,
Theranostics,
2022,
12, 2115. [
Crossref], [
Google Scholar], [
Publisher]
[6]. A.M. Florea, D. Büsselberg, Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects,
Cancers,
2011,
3, 1351-1371. [
Crossref], [
Google Scholar], [
Publisher]
[7]. L. Zhong, Y. Li, L. Xiong, W. Wang, M. Wu, T. Yuan, W. Yang, C. Tian, Z. Miao, T. Wang, Small molecules in targeted cancer therapy: Advances, challenges, and future perspectives,
Signal Transduction and Targeted Therapy,
2021,
6, 201. [
Crossref], [
Google Scholar], [
Publisher]
[8]. A. Bhargava, U.N. Vaishampayan, Satraplatin: Leading the new generation of oral platinum agents,
Expert Opinion on Investigational Drugs,
2009,
18, 1787-1797. [
Crossref], [
Google Scholar], [
Publisher]
[9]. A.J. Armstrong, E.S. Garrett-Mayer, Y.-C.O. Yang, R. De Wit, I.F. Tannock, M. Eisenberger, A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis,
Clinical Cancer Research,
2007,
13, 6396-6403. [
Crossref], [
Google Scholar], [
Publisher]
[10]. D. Tsvetkova, S. Ivanova, Application of approved cisplatin derivatives in combination therapy against different cancer diseases,
Molecules,
2022,
27, 2466. [
Crossref], [
Google Scholar], [
Publisher]
[11]. S. Dasari, P.B. Tchounwou, Cisplatin in cancer therapy: Molecular mechanisms of action,
European Journal of Pharmacology,
2014,
740, 364-378. [
Crossref], [
Google Scholar], [
Publisher]
[12]. A.-M. Florea, D. Büsselberg, Cisplatin as an anti-tumor drug: Cellular mechanisms of activity, drug resistance and induced side effects,
Cancers,
2011,
3, 1351-1371. [
Crossref], [
Google Scholar], [
Publisher]
[13]. V. O'neill, C. Twelves, Oral cancer treatment: Developments in chemotherapy and beyond,
British Journal of Cancer,
2002,
87, 933-937. [
Crossref], [
Google Scholar], [
Publisher]
[14]. A. Granja, M. Pinheiro, S. Reis, Epigallocatechin gallate nanodelivery systems for cancer therapy,
Nutrients,
2016,
8, 307. [
Crossref], [
Google Scholar], [
Publisher]
[15]. L. Galluzzi, I. Vitale, J. Michels, C. Brenner, G. Szabadkai, A. Harel-Bellan, M. Castedo, G. Kroemer, Systems biology of cisplatin resistance: Past, present and future,
Cell Death & Disease,
2014,
5, e1257-e1257. [
Crossref], [
Google Scholar], [
Publisher]
[16]. C. Stewart, C. Ralyea, S. Lockwood, Ovarian cancer: An integrated review, Seminars in Oncology Nursing,
2019, 35, 151-156. [
Crossref], [
Google Scholar], [
Publisher]
[17]. H. Song, W. Li, R. Qi, L. Yan, X. Jing, M. Zheng, H. Xiao, Delivering a photosensitive transplatin prodrug to overcome cisplatin drug resistance,
Chemical Communications,
2015,
51, 11493-11495. [
Crossref], [
Google Scholar], [
Publisher]
[18]. S. Rottenberg, C. Disler, P. Perego, The rediscovery of platinum-based cancer therapy,
Nature Reviews Cancer,
2021,
21, 37-50. [
Crossref], [
Google Scholar], [
Publisher]
[19]. J. Holford, S. Sharp, B. Murrer, M. Abrams, L. Kelland, In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473,
British Journal of Cancer,
1998,
77, 366-373. [
Crossref], [
Google Scholar], [
Publisher]
[20]. F. Wu, Y. Du, J. Yang, B. Shao, Z. Mi, Y. Yao, Y. Cui, F. He, Y. Zhang, P. Yang, Peroxidase-like active nanomedicine with dual glutathione depletion property to restore oxaliplatin chemosensitivity and promote programmed cell death,
ACS Nano,
2022,
16, 3647-3663. [
Crossref], [
Google Scholar], [
Publisher]
[21]. G. Doshi, G. Sonpavde, C.N. Sternberg, Clinical and pharmacokinetic evaluation of satraplatin,
Expert Opinion on Drug Metabolism & Toxicology,
2012,
8, 103-111. [
Crossref], [
Google Scholar], [
Publisher]
[22]. H. Choy, Satraplatin: An orally available platinum analog for the treatment of cancer,
Expert Review of Anticancer Therapy,
2006,
6, 973-982. [
Crossref], [
Google Scholar], [
Publisher]
[23]. E.L. van Dorp, A. Yassen, A. Dahan, Naloxone treatment in opioid addiction: The risks and benefits,
Expert Opinion on Drug Safety,
2007,
6, 125-132. [
Crossref], [
Google Scholar], [
Publisher]
[24]. L. Kelland, Broadening the clinical use of platinum drug–based chemotherapy with new analogues: Satraplatin and picoplatin,
Expert Opinion on Investigational Drugs,
2007,
16, 1009-1021. [
Crossref], [
Google Scholar], [
Publisher]
[25]. Y.R. Zheng, K. Suntharalingam, T.C. Johnstone, H. Yoo, W. Lin, J.G. Brooks, S.J. Lippard, Pt (IV) prodrugs designed to bind non-covalently to human serum albumin for drug delivery,
Journal of the American Chemical Society,
2014,
136, 8790-8798. [
Crossref], [
Google Scholar], [
Publisher]
[26]. M. Frezza, S. Hindo, D. Chen, A. Davenport, S. Schmitt, D. Tomco, Q. Ping Dou, Novel metals and metal complexes as platforms for cancer therapy,
Current Pharmaceutical Design,
2010,
16, 1813-1825. [
Crossref], [
Google Scholar], [
Publisher]
[27]. X. Yuan, W. Zhang, Y. He, J. Yuan, D. Song, H. Chen, W. Qin, X. Qian, H. Yu, Z. Guo, Proteomic analysis of cisplatin-and oxaliplatin-induced phosphorylation in proteins bound to Pt–DNA adducts,
Metallomics,
2020,
12, 1834-1840. [
Crossref], [
Google Scholar], [
Publisher]
[28]. H. Choy, C. Park, M. Yao, Current status and future prospects for satraplatin, an oral platinum analogue,
Clinical Cancer Research,
2008,
14, 1633-1638. [
Crossref], [
Google Scholar], [
Publisher]
[29]. J. Zhou, Y. Kang, L. Chen, H. Wang, J. Liu, S. Zeng, L. Yu, The drug-resistance mechanisms of five platinum-based antitumor agents,
Frontiers in Pharmacology,
2020,
11, 343. [
Crossref], [
Google Scholar], [
Publisher]
[31]. R.L. Lucaciu, A.C. Hangan, B. Sevastre, L.S. Oprean, Metallo-drugs in cancer therapy: Past, present and future,
Molecules,
2022,
27, 6485. [
Crossref], [
Google Scholar], [
Publisher]
[32]. O. Eje, C. Ogbonna, C. Onoyima, F. Nduka, Huntington disease: Mechanism of pathogenesis and recent developments in its therapeutic strategies-A short review,
Journal of Chemical Reviews,
2023,
5, 129-142. [
Crossref], [
Google Scholar], [
Publisher]
[33]. L. Mehrdana, H. Safari, A. Maher, Crisis management in the face of covid-19 to control drug chemistry for cancer patients in different countries: A review study,
Journal of Chemical Reviews,
2021,
3, 232-246. [
Crossref], [
Google Scholar], [
Publisher]
[34]. R. Huang, P.K. Zhou, DNA damage repair: Historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy,
Signal Transduction and Targeted Therapy,
2021,
6, 254. [
Crossref], [
Google Scholar], [
Publisher]
[35]. J. Bergstrom, M. Kurtz, D. Rew, A. Amend, J. Karkas, R. Bostedor, V. Bansal, C. Dufresne, F. VanMiddlesworth, O. Hensens, Zaragozic acids: A family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase,
Proceedings of the National Academy of Sciences,
1993,
90, 80-84. [
Crossref], [
Google Scholar], [
Publisher]
[36]. C.I. Liu, W.Y. Jeng, W.J. Chang, T.P. Ko, A.H.J. Wang, Binding modes of zaragozic acid A to human squalene synthase and staphylococcal dehydrosqualene synthase,
Journal of Biological Chemistry,
2012,
287, 18750-18757. [
Crossref], [
Google Scholar], [
Publisher]
[37]. L. Ma, W. Cho, E.R. Nelson, Our evolving understanding of how 27-hydroxycholesterol influences cancer,
Biochemical pharmacology,
2022,
196, 114621. [
Crossref], [
Google Scholar], [
Publisher]
[38]. I. Giacomini, F. Gianfanti, M.A. Desbats, G. Orso, M. Berretta, T. Prayer-Galetti, E. Ragazzi, V. Cocetta, Cholesterol metabolic reprogramming in cancer and its pharmacological modulation as therapeutic strategy,
Frontiers in Oncology,
2021,
11, 682911. [
Crossref], [
Google Scholar], [
Publisher]
[39]. S. Mukhopadhyay, C.M. Barnés, A. Haskel, S.M. Short, K.R. Barnes, S.J. Lippard, Conjugated platinum (IV)− peptide complexes for targeting angiogenic tumor vasculature,
Bioconjugate Chemistry,
2008,
19, 39-49. [
Crossref], [
Google Scholar], [
Publisher]
[40]. M. Xie, D. Liu, Y. Yang, Anti-cancer peptides: Classification, mechanism of action, reconstruction and modification,
Open Biology,
2020,
10, 200004. [
Crossref], [
Google Scholar], [
Publisher]
[41]. M. Chehelgerdi, M. Chehelgerdi, O.Q.B. Allela, R.D.C. Pecho, N. Jayasankar, D.P. Rao, T. Thamaraikani, M. Vasanthan, P. Viktor, N. Lakshmaiya, Progressing nanotechnology to improve targeted cancer treatment: Overcoming hurdles in its clinical implementation,
Molecular Cancer,
2023,
22, 169. [
Crossref], [
Google Scholar], [
Publisher]
[42]. G.J. Yoshida, Metabolic reprogramming: the emerging concept and associated therapeutic strategies,
Journal of experimental & clinical cancer research,
2015,
34, 1-10. [
Crossref], [
Google Scholar], [
Publisher]
[43]. E. Bortolamiol, F. Visentin, T. Scattolin, Recent advances in bioconjugated transition metal complexes for cancer therapy,
Applied Sciences,
2023,
13, 5561. [
Crossref], [
Google Scholar], [
Publisher]
[44]. S. Norn, H. Permin, E. Kruse, P.R. Kruse, Mercury--a major agent in the history of medicine and alchemy,
Dansk Medicinhistorisk Arbog,
2008,
36, 21-40. [
Google Scholar], [
Publisher]
[45]. S. Waxman, K.C. Anderson, History of the development of arsenic derivatives in cancer therapy,
The Oncologist,
2001,
6, 3-10. [
Crossref], [
Google Scholar], [
Publisher]
[46]. S.P. Pricker, Medical uses of gold compounds: Past, present and future,
Gold Bulletin,
1996,
29, 53-60. [
Google Scholar], [
Publisher]
[47]. U. Jungwirth, C.R. Kowol, B.K. Keppler, C.G. Hartinger, W. Berger, P. Heffeter, Anticancer activity of metal complexes: Involvement of redox processes,
Antioxidants & Redox Signaling,
2011, 15. [
Crossref], [
Google Scholar], [
Publisher]
[48]. H.F. Ji, X.J. Li, H.Y. Zhang, Natural products and drug discovery: can thousands of years of ancient medical knowledge lead us to new and powerful drug combinations in the fight against cancer and dementia?,
EMBO Reports,
2009,
10, 194-200. [
Crossref], [
Google Scholar], [
Publisher]
[49]. M. Frezza, S. Hindo, D. Chen, A. Davenport, S. Schmitt, D. Tomco, Q. Ping Dou, Novel metals and metal complexes as platforms for cancer therapy,
Current Pharmaceutical Design,
2010,
16, 1813-1825. [
Crossref], [
Google Scholar], [
Publisher]
[50]. P.C. Bruijnincx, P.J. Sadler, New trends for metal complexes with anticancer activity,
Current Opinion in Chemical Biology,
2008,
12, 197-206. [
Crossref], [
Google Scholar], [
Publisher]
[51]. V. Mourino, J.P. Cattalini, A.R. Boccaccini, Metallic ions as therapeutic agents in tissue engineering scaffolds: An overview of their biological applications and strategies for new developments,
Journal of the Royal Society Interface,
2012,
9, 401-419. [
Crossref], [
Google Scholar], [
Publisher]
[52]. B.T. Benedetti, E.J. Peterson, P. Kabolizadeh, A. Martínez, R. Kipping, N.P. Farrell, Effects of noncovalent platinum drug–protein interactions on drug efficacy: Use of fluorescent conjugates as probes for drug metabolism,
Molecular Pharmaceutics,
2011,
8, 940-948. [
Crossref], [
Google Scholar], [
Publisher]
[53]. V. Milacic, D. Fregona, Q.P. Dou, Gold complexes as prospective metal-based anticancer drugs,
Histology and Histopathology,
2008. [
Google Scholar], [
Publisher]
[54]. L. Zhong, Y. Li, L. Xiong, W. Wang, M. Wu, T. Yuan, W. Yang, C. Tian, Z. Miao, T. Wang, Small molecules in targeted cancer therapy: Advances, challenges, and future perspectives,
Signal Transduction and Targeted Therapy,
2021,
6, 201. [
Crossref], [
Google Scholar], [
Publisher]
[55]. E.L. Lieu, T. Nguyen, S. Rhyne, J. Kim, Amino acids in cancer,
Experimental & Molecular Medicine,
2020,
52, 15-30. [
Crossref], [
Google Scholar], [
Publisher]
[56]. M.J. Lukey, W.P. Katt, R.A. Cerione, Targeting amino acid metabolism for cancer therapy,
Drug Discovery Today,
2017,
22, 796-804. [
Crossref], [
Google Scholar], [
Publisher]
[57]. J.H. Kim, E. Reeder, S. Parkin, S.G. Awuah, Gold (I/III)-phosphine complexes as potent antiproliferative agents,
Scientific Reports,
2019,
9, 12335. [
Crossref], [
Google Scholar], [
Publisher]
[58]. J. Verma, C. Warsame, R.K. Seenivasagam, N.K. Katiyar, E. Aleem, S. Goel, Nanoparticle-mediated cancer cell therapy: Basic science to clinical applications,
Cancer and Metastasis Reviews,
2023, 1-27. [
Crossref], [
Google Scholar], [
Publisher]
[59]. J.L. Cooper, P. Robinson, The argument for making large classes seem small,
New Directions for Teaching and Learning,
2000,
2000, 5-16. [
Crossref], [
Google Scholar], [
Publisher]
[60]. R.K. Jain, T. Stylianopoulos, Delivering nanomedicine to solid tumors,
Nature Reviews Clinical Oncology,
2010,
7, 653-664. [
Crossref], [
Google Scholar], [
Publisher]
[61]. C.M.J. Hu, L. Zhang, Therapeutic nanoparticles to combat cancer drug resistance,
Current Drug Metabolism,
2009,
10, 836-841. [
Crossref], [
Google Scholar], [
Publisher]
[62]. D. Peer, J.M. KarP, S. Hong, O.C. Farokhzad, R. Margalit, R. Langer, Nanocarriers as an emerging platform for cancer therapy,
Nature Nanotechnology,
2007,
2, 755. [
Crossref], [
Google Scholar], [
Publisher]
[63]. C. Naud, C. Thébault, M. Carrière, Y. Hou, R. Morel, F. Berger, B. Diény, H. Joisten, Cancer treatment by magneto-mechanical effect of particles, a review,
Nanoscale Advances,
2020,
2, 3632-3655. [
Crossref], [
Google Scholar], [
Publisher]
[64]. C.J. Murphy, A.M. Vartanian, F.M. Geiger, R.J. Hamers, J. Pedersen, Q. Cui, C.L. Haynes, E.E. Carlson, R. Hernandez, R.D. Klaper, Biological responses to engineered nanomaterials: Needs for the next decade,
ACS Central Science,
2015,
1, 117-123. [
Crossref], [
Google Scholar], [
Publisher]
[65]. A.D. Morton, Waiting for gramsci: State formation, passive revolution and the international,
Millennium,
2007,
35, 597-621. [
Crossref], [
Google Scholar], [
Publisher]
[66]. A. Ghossain, M.A. Ghossain, History of mastectomy before and after Halsted,
Le Journal medical libanais. The Lebanese Medical Journal,
2009,
57, 65-71. [
Google Scholar], [
Publisher]
[67]. R. Sankaranarayanan, K. Ramadas, S. Thara, R. Muwonge, G. Thomas, G. Anju, B. Mathew, Long term effect of visual screening on oral cancer incidence and mortality in a randomized trial in Kerala, India,
Oral Oncology,
2013,
49, 314-321. [
Crossref], [
Google Scholar], [
Publisher]
[68]. K. Wang, J.E. Tepper, Radiation therapy‐associated toxicity: Etiology, management, and prevention,
CA: A Cancer Journal for Clinicians,
2021,
71, 437-454. [
Crossref], [
Google Scholar], [
Publisher]
[69]. S.M. Bird, The 1959 meeting in Vienna on controlled clinical trials–A methodological landmark,
Journal of the Royal Society of Medicine,
2015,
108, 372-375. [
Crossref], [
Google Scholar], [
Publisher]
[70]. B. Cho, Intensity-modulated radiation therapy: a review with a physics perspective,
Radiation Oncology Journal,
2018,
36, 1. [
Crossref], [
Google Scholar], [
Publisher]
[71]. L.S. Goodman, M.M. Wintrobe, W. Dameshek, M.J. Goodman, A. Gilman, M.T. McLennan, Nitrogen mustard therapy: Use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders,
Journal of the American Medical Association,
1946,
132, 126-132. [
Crossref], [
Google Scholar], [
Publisher]
[72]. H.S. Oberoi, N.V. Nukolova, A.V. Kabanov, T.K. Bronich, Nanocarriers for delivery of platinum anticancer drugs,
Advanced Drug Delivery Reviews,
2013,
65, 1667-1685. [
Crossref], [
Google Scholar], [
Publisher]
[73]. T.C. Johnstone, G.Y. Park, S.J. Lippard, Understanding and improving platinum anticancer drugs–phenanthriplatin,
Anticancer Research,
2014,
34, 471-476. [
Google Scholar], [
Publisher]
[74]. P. Krzyszczyk, A. Acevedo, E.J. Davidoff, L.M. Timmins, I. Marrero-Berrios, M. Patel, C. White, C. Lowe, J.J. Sherba, C. Hartmanshenn, The growing role of precision and personalized medicine for cancer treatment,
Technology,
2018,
6, 79-100. [
Crossref], [
Google Scholar], [
Publisher]
[75]. T.C. Johnstone, K. Suntharalingam, S.J. Lippard, The next generation of platinum drugs: targeted Pt (II) agents, nanoparticle delivery, and Pt (IV) prodrugs,
Chemical Reviews,
2016,
116, 3436-3486. [
Crossref], [
Google Scholar], [
Publisher]
[76]. G. Rezanejade Bardajee, S. Ghavami, S.S. Hosseini, A review on pH and temperature responsive gels in drug delivery,
Journal of Chemical Reviews,
2020,
2, 80-89. [
Crossref], [
Google Scholar], [
Publisher]
[77]. I.W. Achkar, N. Abdulrahman, H. Al-Sulaiti, J.M. Joseph, S. Uddin, F. Mraiche, Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway,
Journal of Translational Medicine,
2018,
16, 1-12. [
Crossref], [
Google Scholar], [
Publisher]
[78]. S. Dilruba, G.V. Kalayda, Platinum-based drugs: past, present and future,
Cancer Chemotherapy and Pharmacology,
2016,
77, 1103-1124. [
Crossref], [
Google Scholar], [
Publisher]
[79]. S. Zhu, N. Pabla, C. Tang, L. He, Z. Dong, DNA damage response in cisplatin-induced nephrotoxicity,
Archives of Toxicology,
2015,
89, 2197-2205. [
Crossref], [
Google Scholar], [
Publisher]
[80]. A. Brown, S. Kumar, P.B. Tchounwou, Cisplatin-based chemotherapy of human cancers,
Journal of Cancer Science & Therapy,
2019,
11. [
Google Scholar], [
Publisher]
[81]. M.-P. Mingeot-Leclercq, P.M. Tulkens, Aminoglycosides: Nephrotoxicity,
Antimicrobial Agents and Chemotherapy,
1999,
43, 1003-1012. [
Crossref], [
Google Scholar], [
Publisher]
[82]. J. Małyszko, K. Kozłowska, L. Kozłowski, J. Małyszko, Nephrotoxicity of anticancer treatment,
Nephrology Dialysis Transplantation,
2017,
32, 924-936. [
Crossref], [
Google Scholar], [
Publisher]
[83]. S. Schoch, S. Gajewski, J. Rothfuß, A. Hartwig, B. Köberle, Comparative study of the mode of action of clinically approved platinum-based chemotherapeutics,
International Journal of Molecular Sciences,
2020,
21, 6928. [
Crossref], [
Google Scholar], [
Publisher]
[84]. B. Mansoori, A. Mohammadi, S. Davudian, S. Shirjang, B. Baradaran, The different mechanisms of cancer drug resistance: a brief review,
Advanced Pharmaceutical Bulletin,
2017,
7, 339. [
Crossref], [
Google Scholar], [
Publisher]
[85]. G. Fang, A. Zhang, L. Zhu, Q. Wang, F. Sun, B. Tang, Nanocarriers containing platinum compounds for combination chemotherapy,
Frontiers in Pharmacology,
2022,
13, 1050928. [
Crossref], [
Google Scholar], [
Publisher]
[86]. F. De Castro, E. Stefàno, E. De Luca, M. Benedetti, F.P. Fanizzi, Platinum-nucleos (t) ide compounds as possible antimetabolites for antitumor/antiviral therapy: Properties and perspectives,
Pharmaceutics,
2023,
15, 941. [
Crossref], [
Google Scholar], [
Publisher]
[87]. R. Singh, J.W. Lillard Jr, Nanoparticle-based targeted drug delivery,
Experimental and Molecular Pathology,
2009,
86, 215-223. [
Crossref], [
Google Scholar], [
Publisher]
[88]. S.R. McWhinney, R.M. Goldberg, H.L. McLeod, Platinum neurotoxicity pharmacogenetics,
Molecular Cancer Therapeutics,
2009,
8, 10-16. [
Crossref], [
Google Scholar], [
Publisher]
[89]. I. Predarska, M. Saoud, I. Morgan, P. Lönnecke, G.N. Kaluđerović, E. Hey-Hawkins, Triphenyltin (IV) carboxylates with exceptionally high cytotoxicity against different breast cancer cell lines,
Biomolecules,
2023,
13, 595. [
Crossref], [
Google Scholar], [
Publisher]
[90]. T.Y. Seiwert, J.K. Salama, E.E. Vokes, The chemoradiation paradigm in head and neck cancer,
Nature Clinical Practice Oncology,
2007,
4, 156-171. [
Crossref], [
Google Scholar], [
Publisher]
[91]. A. Ardizzoni, L. Boni, M. Tiseo, F.V. Fossella, J.H. Schiller, M. Paesmans, D. Radosavljevic, A. Paccagnella, P. Zatloukal, P. Mazzanti, Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non–small-cell lung cancer: an individual patient data meta-analysis,
Journal of the National Cancer Institute,
2007,
99, 847-857. [
Crossref], [
Google Scholar], [
Publisher]
[92]. L. Hess, M. Benham-Hutchins, T. Herzog, C.-H. Hsu, D. Malone, G. Skrepnek, M. Slack, D. Alberts, A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer,
International Journal of Gynecologic Cancer,
2007,
17. [
Crossref], [
Google Scholar], [
Publisher]
[93]. Z.N. Lei, Q. Tian, Q.X. Teng, J.N. Wurpel, L. Zeng, Y. Pan, Z.S. Chen, Understanding and targeting resistance mechanisms in cancer,
MedComm,
2023,
4, e265. [
Crossref], [
Google Scholar], [
Publisher]
[94]. E.L. Sauers, T.C.V. McLeod, R.C. Bay, Practice-based research networks, part I: clinical laboratories to generate and translate research findings into effective patient care,
Journal of Athletic Training,
2012,
47, 549-556. [
Crossref], [
Google Scholar], [
Publisher]
[95]. W.M. Tierney, C.C. Oppenheimer, B.L. Hudson, J. Benz, A. Finn, J.M. Hickner, D. Lanier, D.S. Gaylin, A national survey of primary care practice-based research networks,
The Annals of Family Medicine,
2007,
5, 242-250. [
Crossref], [
Google Scholar], [
Publisher]
[96]. D.S. Kadam, S.G. Patil, D. Mammen, S.D. Kadam, V.S. More, In silico molecular docking againstc-KIT tyrosine kinase and ADME studies of 4-thiazolidinone derivatives,
Journal of Appllied Organometallic Chemistry,
2023,
3, 13-27. [
Crossref], [
Publisher]
[97]. M.B. Swami, G.R. Nagargoje, S.R. Mathapati, A.S. Bondge, A.H. Jadhav, S.P. Panchgalle, V.S. More, A magnetically recoverable and highly effectual Fe
3O
4 encapsulated MWCNTs nanocomposite for synthesis of 1,8-dioxo-octahydroxanthene derivatives,
Journal of Appllied Organometallic Chemistry,
2023,
3, 184-198. [
Crossref], [
Google Scholar], [
Publisher]
[98]. G.R. Nagargoje, A.S. Bondge, P.D. Kadam, K.I. Momin, S.B. Zangade, D.D. Kadam, S.P. Panchgalle, V.S. More. Quantification of Langlois Reagent by
19F-NMR Spectroscopy,
Journal of Appllied Organometallic Chemistry,
2023,
3, 213-223. [
Crossref], [
Publisher]
[99]. A. Lande, B. Kolapwar, P. Bhujbal, K. Karamunge, V. More, Preparation, characterization, and biological relevaance of Co, Ni, and Zn complexes derived from 6, 6'-((1
E, 1'
E)-((1, 3-phenylenebis (methylene))
bis (azanylylidene))
bis (methanylyidene))-
bis (2, 4-dibromophenol),
Rasayan Journal of Chemistry,
2023,
16, 1063-1068. [
Crossref], [
Google Scholar], [
Publisher]